RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Molecular Pharmacology (USA) Stock

Molecular Pharmacology (USA) P/S 2024

Molecular Pharmacology (USA) P/S

0

Ticker

MLPH

ISIN

US60852T1097

WKN

A0HHDZ

As of Oct 1, 2024, Molecular Pharmacology (USA)'s P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Molecular Pharmacology (USA) P/S history

Molecular Pharmacology (USA) Aktienanalyse

What does Molecular Pharmacology (USA) do?

The company Molecular Pharmacology (USA) Ltd is a biotechnology company based in the United States that specializes in the research and development of innovative drugs for the treatment of diseases. It was founded in Illinois in 2000 and has since been headquartered in Lincolnshire, Illinois. Molecular Pharmacology (USA) Ltd focuses on producing high-quality pharmaceutical agents that work at the molecular level and target specific objectives. Using advanced technologies such as computer-aided drug design (CADD) and high-throughput screening (HTS), the company identifies new drug candidates that specifically target certain diseases. The main focus of Molecular Pharmacology (USA) Ltd is the development of drugs for the treatment of cancer, inflammation, and metabolic diseases. In recent years, the company has also focused on other diseases, such as neurological disorders. Molecular Pharmacology (USA) Ltd divides its offerings into various areas to meet the diverse needs of customers. One of these areas is the provision of active ingredients for the pharmaceutical industry. The company provides high-quality pharmaceutical agents that can be used by other companies for further drug development and production. Another area is the development of its own drugs that can be used to combat various diseases. Molecular Pharmacology (USA) Ltd focuses on the identification and development of new drug candidates that specifically target the causes of diseases and enable effective treatment. Molecular Pharmacology (USA) Ltd also offers services to support customers in the identification and characterization of drug candidates. Customers can rely on the company's experience and expertise to support them in the development of new drugs. Some of the key products of Molecular Pharmacology (USA) Ltd include small molecules, antibodies, peptides, and natural compounds. These provide a high level of efficacy and safety in combating various diseases and thus serve as an important foundation for the development of new drugs. In recent years, Molecular Pharmacology (USA) Ltd has also increased its investments in collaboration with other companies and research institutions. This aims to leverage synergies to jointly identify and develop new drug candidates. An example of this is the collaboration with universities and research institutions specializing in the study of certain diseases. In summary, Molecular Pharmacology (USA) Ltd is a renowned biotechnology company that specializes in the research and development of innovative drugs for the treatment of diseases. The company divides its offerings into various areas and provides services to other companies and research institutions. Molecular Pharmacology (USA) Ltd is thus an important player in the field of drug development and contributes to saving many lives. Molecular Pharmacology (USA) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Molecular Pharmacology (USA)'s P/S Ratio

Molecular Pharmacology (USA)'s Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Molecular Pharmacology (USA)'s P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Molecular Pharmacology (USA)'s stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Molecular Pharmacology (USA)’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Molecular Pharmacology (USA) stock

What is the price-to-earnings ratio of Molecular Pharmacology (USA)?

The price-earnings ratio of Molecular Pharmacology (USA) is currently 0.

How has the price-earnings ratio of Molecular Pharmacology (USA) changed compared to last year?

The price-to-earnings ratio of Molecular Pharmacology (USA) has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Molecular Pharmacology (USA) high compared to other companies?

Yes, the price-to-earnings ratio of Molecular Pharmacology (USA) is high compared to other companies.

How does an increase in the price-earnings ratio of Molecular Pharmacology (USA) affect the company?

An increase in the price-earnings ratio of Molecular Pharmacology (USA) would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Molecular Pharmacology (USA) affect the company?

A decrease in the price-earnings ratio of Molecular Pharmacology (USA) would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Molecular Pharmacology (USA)?

Some factors that influence the price-earnings ratio of Molecular Pharmacology (USA) are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Molecular Pharmacology (USA) pay?

Over the past 12 months, Molecular Pharmacology (USA) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Molecular Pharmacology (USA) is expected to pay a dividend of 0 USD.

What is the dividend yield of Molecular Pharmacology (USA)?

The current dividend yield of Molecular Pharmacology (USA) is .

When does Molecular Pharmacology (USA) pay dividends?

Molecular Pharmacology (USA) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Molecular Pharmacology (USA)?

Molecular Pharmacology (USA) paid dividends every year for the past 0 years.

What is the dividend of Molecular Pharmacology (USA)?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Molecular Pharmacology (USA) located?

Molecular Pharmacology (USA) is assigned to the '-' sector.

Wann musste ich die Aktien von Molecular Pharmacology (USA) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Molecular Pharmacology (USA) from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Molecular Pharmacology (USA) pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Molecular Pharmacology (USA) in the year 2023?

In the year 2023, Molecular Pharmacology (USA) distributed 0 USD as dividends.

In which currency does Molecular Pharmacology (USA) pay out the dividend?

The dividends of Molecular Pharmacology (USA) are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Molecular Pharmacology (USA)

Our stock analysis for Molecular Pharmacology (USA) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Molecular Pharmacology (USA) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.